Sfoglia per AUTORE
TUCCI M
Collezione AOU San Luigi di Orbassano

  

Items : 77

Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2025 Feb 6;209:104627. doi: 10.1016/j.critrevonc.2025.104627.
2025
AOU San Luigi di Orbassano

Colombo C; De Leo S; Campisi I; Palesandro E; Turco F; Buttigliero C; Fugazzola L; Tucci M;

Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2025 Feb;23(1):102255. doi: 10.1016/j.clgc.2024.102255. Epub 2024 Nov 1.
2025
ASL Asti
AOU San Luigi di Orbassano

Cinieri S; Di Maio M; Tucci M; De Giorgi U; Russo A; Caffo O; Di Stefano RF; Turco F; Poletto S; Calabrese M; Saporita I; Buttigliero C;

Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2024 Sep;27(3):385-392. doi: 10.1038/s41391-023-00775-y. Epub 2023 De
2024
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Cathomas R; Tombal B; Smith MR; Fizazi K; Treglia G; Turco F; Gillessen S; Di Maio M; Vogl UM; Tucci M; Buttigliero C; Di Maio M; Cathomas R; Tombal B; Smith MR; Fizazi K; Treglia G; Gillessen S; Turco F; Tucci M; Vogl UM;

Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Oct;22(5):102138. doi: 10.1016/j.clgc.2024.102138. Epub 2024 Jun 12.
2024
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tucci M; Scagliotti GV; Di Maio M; Palesandro E; Poletto S; Calabrese M; Saporita I; Crespi V; Di Stefano RF; Farinea G; Fossati N; Gallina A; Zilli T; Vogl UM; Buttigliero C; Delcuratolo MD; Gillessen S; Turco F;

2024
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Carfì FM; Calabrese M; Saporita I; Pisano C; Delcuratolo MD; Turco F; Di Stefano RF; Samuelly A; Buttigliero C;

2024
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Di Stefano FR; Audisio M; Turco F; Delcuratolo MD; Poletto S; Saporita I; Carfì F; Calabrese M; Farinea G; Buttigliero C;

TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7.
2024
ASL Cuneo 2
ASL Asti
ASL Città di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Tucci M; Gennari A; Maio MD; Buttigliero C; Ortega C; Rossi M; Vellani G; Airoldi M; Vormola R; Numico G; Depetris I; Comandone A; Buosi R; Stevani I; Guglielmini P; Icardi M; Dionisio R; Cattrini C; Vignani F; Brusa F; Prati V; Ruatta F; Filippi R; Mennitto A; Vana F; Fea E; Vanella P; Pisano C; Turco F; et alii...

Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2023 Jan;181:103881. doi: 10.1016/j.critrevonc.2022.103881. Epub 2022 Nov 24
2023
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Scagliotti GV; Di Maio M; Brusa F; Audisio A; Di Stefano RF; Ungaro A; Audisio M; Samuelly A; Turco F; Tucci M; Delcuratolo MD;

Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer. in International journal of molecular sciences / Int J Mol Sci. 2023 Dec 20;25(1):78. doi: 10.3390/ijms25010078.
2023
ASL Asti
AOU San Luigi di Orbassano

Farinea G; Poletto S; Carfì FM; Di Stefano RF; Vogl UM; Castro E; Gillessen S; Turco F; Saporita I; Calabrese M; Tucci M; Buttigliero C;

2023
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Scagliotti GV; Di Maio M; Parlagreco E; Ungaro A; Audisio M; Audisio A; Samuelly A; Pisano C; Urban S; Tucci M; Angusti T; Parente A; Di Stefano RF; Turco F; Turco F; Tucci M; Angusti T; Parente A; Di Stefano RF; Urban S; Pisano C; Samuelly A; Audisio A; Audisio M; Parlagreco E; Ungaro A; Scagliotti GV; Di Maio M; et alii...

New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Jun;174:103682. doi: 10.1016/j.critrevonc.2022.103682. Epub 2022 Apr 11
2022
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Di Maio M; Scagliotti GV; Ortega C; Di Prima L; Audisio A; Turco F; Ungaro A; Di Stefano RF; Parlagreco E; Tucci M; Audisio M;

2022
ASL Asti
AOU San Luigi di Orbassano

Di Prima L; Di Stefano RF; Ungaro A; Audisio M; Parlagreco E; Delcuratolo MD; Buttigliero C; Audisio A; Turco F; Tucci M;

2022
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Di Maio M; Scagliotti GV; Delcuratolo MD; Turco F; Di Prima L; Pisano C; Audisio A; Tucci M; Ungaro A;

Prognostic factors in metastatic castration resistant prostate cancer patients treated with radium-223: a retrospective study. in Minerva urology and nephrology / Minerva Urol Nephrol. 2022 Dec;74(6):703-713. doi: 10.23736/S2724-6051.22.04701-2. Epub 2022 Feb 11.
2022
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; DI Maio M; Tucci M; Scagliotti GV; Pisano C; Samuelly A; Turco F; Parente A; Bungaro M; DI Stefano RF; Angusti T;

Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. in Cancer communications (London, England) / Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22.
2022
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Scagliotti GV; Buttigliero C; Di Maio M; Ortega C; Ungaro A; Audisio M; Pisano C; Audisio A; Di Stefano RF; Tucci M; Delcuratolo MD; Turco F;

2021
ASL Asti
AO Cuneo
ASL Città di Torino
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Berruti A; Tucci M; Gennari A; Baier S; Bellissimo AR; Ciccone G; Montagnani F; Comandone A; Chiappino I; Dal Canton O; Masini C; Sacco C; Zamparini M; Sirotova Z; Fea E; Valcamonico F; Vanella P; Ortega C; Buttigliero C; Prati V; Bianchi S; Mosca A; Dalla Volta A; Amoroso D;

Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients. in Future oncology (London, England) / Future Oncol. 2021 Mar;17(7):807-815. doi: 10.2217/fon-2020-0391. Epub 2021 Jan 29.
2021
ASL Asti
AOU San Luigi di Orbassano

Salgarello M; Borsatti E; Pignata S; Zichi C; Filice A; Murabito A; Biasco E; Fanti S; Palermo A; Alongi P; Alongi F; Bortolus R; Facchini G; Baldari S; Tucci M; Pinto C; Costa RP; Sbrana A; Monari F; Caffo O; Frantellizzi V; Spada M; Cortesi E; Vincentis G;

Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC. in Endocrine-related cancer / Endocr Relat Cancer. 2021 Jun 2;28(7):R207-R216. doi: 10.1530/ERC-20-0457.
2021
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Scagliotti GV; Di Maio M; Pisano C; Audisio M; Bungaro M; Tucci M; Di Stefano RF; Samuelly A; Turco F;

Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without (223)Ra. in Cancer biotherapy & radiopharmaceuticals / Cancer Biother Radiopharm. 2021 Jun;36(5):391-396. doi: 10.1089/cbr.2020.4442. Epub 2021 Mar 25.
2021
ASL Asti
AOU San Luigi di Orbassano

Spada M; Salgarello M; Borsatti E; Pignata S; Zichi C; Masini C; Morabito A; Fanti S; Sbrana A; Donner D; Alongi P; Alongi F; Bortolus R; Facchini G; Tucci M; Baldari S; Pinto C; Costa RP; Galli L; Monari F; Caffo O; Frantellizzi V; De Giorgi U; Lo Re G; Cortesi E; De Vincentis G;

Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2021 Jan;157:103185. doi: 10.1016/j.critrevonc.2020.103185. Epub 2020 Nov 27
2021
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; Pisano C; Tucci M; Di Stefano RF; Turco F; Scagliotti GV; Di Maio M;

Adverse event assessment in prostate cancer patients receiving androgen deprivation therapy: are we doing enough? in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):870-872. doi: 10.23736/S2724-6051.21.04817-5.
2021
ASL Asti
AOU San Luigi di Orbassano

Buttigliero C; Tucci M; Turco F;

Prognostic role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. in Minerva urology and nephrology / Minerva Urol Nephrol. 2021 Dec;73(6):803-814. doi: 10.23736/S2724-6051.21.04186-2. Epub 2021 Mar 29.
2021
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Buttigliero C; DI Maio M; Scagliotti GV; Tarenghi F; Bungaro M; Vignani F; Samuelly A; DI Stefano RF; Turco F; Tucci M; Pisano C;

Are tyrosine kinase inhibitors an effective treatment in testicular metastases from kidney cancer? Case report. in Tumori / Tumori. 2021 Dec;107(6):NP149-NP154. doi: 10.1177/03008916211059230. Epub 2021 Nov 11.
2021
ASL Asti
AOU San Luigi di Orbassano

Scagliotti GV; Bollito E; Bungaro M; Samuelly A; Tucci M; Di Stefano RF; Turco F; Buttigliero C;

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). in Clinical Medicine Insights. Oncology / Clin Med Insights Oncol. 2021 Jul 8;15:11795549211021667. doi: 10.1177/11795549211021667. eCollectio
2021
AOU San Luigi di Orbassano

Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A;

2020
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Di Maio M; Tucci M; Gamba T; Necchi A; Buttigliero C; Vignani F; Marandino L;

Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. in JAMA network open / JAMA Netw Open. 2020 Oct 1;3(10):e2021692. doi: 10.1001/jamanetworkopen.2020.21692.
2020
AOU San Luigi di Orbassano

Schmid S; Omlin A; Higano C; Sweeney C; Martinez Chanza N; Mehra N; Kuppen MCP; Beltran H; Conteduca V; Vargas Pivato de Almeida D; Cotait Maluf F; Oh WK; Tsao CK; Sartor O; Ledet E; Di Lorenzo G; Yip SM; Chi KN; Bianchini D; De Giorgi U; Hansen AR; Beer TM; Lavaud P; Morales-Barrera R; Tucci M; Castro E; Karalis K; Bergman AM; Le ML; et alii...

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2020 Oct;31(10):1415-1416. doi: 10.1016/j.annonc.2020.06.005. Epub 2020 Jun 18.
2020
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Procopio G; Mucciarini C; Mosca A; Massari F; Masini C; Fratino L; Ermacora P; Fornarini G; Donini M; Ceresoli GL; Buti S; Bortolus R; Berruti A; Baldessari C; Zagonel V; Caffo O; Buttigliero C; Zucali P; Verri E;

Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2020 Oct;47(11):2633-2638. doi: 10.1007/s00259-020-04796-w. Epub 2020 Ap
2020
AOU San Luigi di Orbassano

Caffo O; Frantellizzi V; Tucci M; Galli L; Monari F; Baldari S; Masini C; Bortolus R; Facchini G; Alongi P; Agostini S; Zichi C; Biasco E; Fanti S; Pignata S; Filice A; Borsatti E; Rossetti S; Spada M; Cortesi E; De Vincentis G;

Survival Outcomes From a Cumulative Analysis of Worldwide Observational Studies on Sequential Use of New Agents in Metastatic Castration-Resistant Prostate Cancer. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2020 Feb;18(1):69-76.e4. doi: 10.1016/j.clgc.2019.09.010. Epub 2019 Sep 27.
2020
AOU San Luigi di Orbassano

Pappagallo G; Galli L; Gelderblom H; Tucci M; De Giorgi U; Zagonel V; Sella A; Bournakis E; Yu EY; Schmid S; Thomsen FB; Bergman A; Bianchini D; Wissing M; Caffo O; Bria E; Sperduti I; Oudard S;

Prognostic role of early PSA drop in castration resistant prostate cancer patients treated with abiraterone acetate or enzalutamide. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2020 Dec;72(6):737-745. doi: 10.23736/S0393-2249.20.03708-X. Epub 2020 Apr 10.
2020
AOU Alessandria
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Di Maio M; Numico G; Scagliotti GV; Guglielmini P; Lacidogna G; Turco F; Pisano C; Vignani F; Di Stefano RF; Tucci M; Sonetto C; Buttigliero C;

Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2020 Aug;152:102994. doi: 10.1016/j.critrevonc.2020.102994. Epub 2020 May 24
2020
ASL Asti
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Tucci M; Di Maio M; Scagliotti GV; Vignani F; Tabbò F; Turco F; Di Stefano RF; Buttigliero C; Pisano C; Leone G;

Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. in Cancer drug resistance (Alhambra, Calif.) / Cancer Drug Resist. 2020 Sep 12;3(4):726-741. doi: 10.20517/cdr.2020.42. eCollection 2020.
2020
ASL Asti
AOU San Luigi di Orbassano

Tucci M; Buttigliero C; Bungaro M;

Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2019 Oct;17(5):332-347.e2. doi: 10.1016/j.clgc.2019.07.007. Epub 2019 Jul 20
2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Novello S; Aglietta M; Tucci M; Buttigliero C; Sonetto C; La Salvia A; Muratori L; Leone G; Trevisi E; Mariniello A; Ghisoni E; Di Stefano RF; Pignataro D; Reale ML; Lombardi P; Zichi C; De Luca E; Marandino L; Scagliotti GV; Perrone F; Di Maio M;

Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era. in Cancer treatment reviews / Cancer Treat Rev. 2019 Mar;74:35-42. doi: 10.1016/j.ctrv.2019.01.002. Epub 2019 Jan 7.
2019
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Scagliotti GV; Veccia A; Rossetti S; Rizzo M; Maines F; Kinspergher S; Di Maio M; Cavaliere C; D'aniello C; Buttigliero C; Tucci M; Caffo O; Facchini G;

2019
ASL Asti
AOU San Luigi di Orbassano

Sigala S; Buttigliero C; Vittorio Scagliotti G; Bedussi F; Dalla Volta A; Pia A; Ferrari L; Tucci M; Roca E; Berruti A;

68Ga-PSMA Uptake in Fibrous Dysplasia. in Clinical nuclear medicine / Clin Nucl Med. 2019 Jun;44(6):e396-e397. doi: 10.1097/RLU.0000000000002546.
2019
AOU San Luigi di Orbassano

Reale ML; Buttigliero C; Tucci M; Giardino R; Poti C;

Prostate cancer management at an Italian tertiary referral center: does multidisciplinary team meeting influence diagnostic and therapeutic decision-making process? A snapshot of the everyday clinical practice. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2019 Dec;71(6):576-582. doi: 10.23736/S0393-2249.19.03231-4. Epub 2019 Sep 4.
2019
AOU San Luigi di Orbassano

De Luca S; Fiori C; Tucci M; Poggio M; Allis S; Bollito E; Solitro F; Passera R; Buttigliero C; Porpiglia F;

Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2019 Aug;17(4):291-298. doi: 10.1016/j.clgc.2019.05.002. Epub 2019 May 13.
2019
AOU San Luigi di Orbassano

Peverelli G; Raimondi A; Ratta R; Verzoni E; Bregni M; Cortesi E; Cartenì G; Fornarini G; Facchini G; Buti S; Galli L; Tucci M; Prisciandaro M; Procopio G;

Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2018 Sep;129:124-132. doi: 10.1016/j.critrevonc.2018.07.004. Epub 2018 Jul 1
2018
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Di Maio M; Ardizzoni A; Zichi C; Gatto L; Vignani F; Tucci M; Buttigliero C; De Luca E; Di Nunno V; Massari F;

Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. in Cancer treatment reviews / Cancer Treat Rev. 2018 Sep;69:215-223. doi: 10.1016/j.ctrv.2018.07.010. Epub 2018 Jul 20.
2018
AO Ordine Mauriziano
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Di Maio M; Filippi AR; Scagliotti GV; Ruo Redda MG; Ricardi U; Di Stefano RF; Leone G; Zichi C; Allis S; Tucci M; Buttigliero C; Buttigliero C; Allis S; Tucci M; Zichi C; Leone G; Di Stefano RF; Ruo Redda MG; Ricardi U; Scagliotti GV; Di Maio M; Filippi AR;

De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. in Cancer treatment reviews / Cancer Treat Rev. 2018 Nov;70:67-74. doi: 10.1016/j.ctrv.2018.08.005. Epub 2018 Aug 11.
2018
AOU San Luigi di Orbassano

Mosillo C; Iacovelli R; Ciccarese C; Fantinel E; Bimbatti D; Brunelli M; Bisogno I; Kinspergher S; Buttigliero C; Tucci M; Caffo O; Tortora G;

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.
2018
AOU San Luigi di Orbassano

Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; et alii...

FOLFOX activity in a rare case of metastatic colonic adenocarcinoma of the tongue: a case report. in BMC cancer / BMC Cancer. 2018 Apr 26;18(1):470. doi: 10.1186/s12885-018-4395-5.
2018
AOU San Luigi di Orbassano

Zichi C; Tampellini M; Tucci M; Sonetto C; Baratelli C; Brizzi MP; Scagliotti GV;

Hormonal treatment and quality of life of prostate cancer patients: new evidence. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2018 Apr;70(2):144-151. doi: 10.23736/S0393-2249.17.03066-1. Epub 2017 Dec 14.
2018
AO Ordine Mauriziano
AOU San Luigi di Orbassano

DI Maio M; Scagliotti GV; Pignataro D; Vignani F; DI Stefano RF; Zichi C; Leone G; Buttigliero C; Tucci M;

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. in OncoTargets and therapy / Onco Targets Ther. 2018 Oct 24;11:7353-7368. doi: 10.2147/OTT.S153764. eCollection 2018.
2018
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Scagliotti GV; Vignani F; Buttigliero C; Zichi C; Tucci M; Di Maio M;

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2017 Sep 6:S1558-7673(17)30275-6. doi: 10.1016/j.clgc.2017.08.020.
2017
AOU San Luigi di Orbassano

Heinrich D; Bektic J; Bergman AM; Caffo O; Cathomas R; Chi KN; Daugaard G; Keizman D; Kindblom J; Kramer G; Olmos D; Omlin A; Sridhar SS; Tucci M; van Oort I; Nilsson S;

2017
AOU San Luigi di Orbassano

Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; et alii...

223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma. in Clinical nuclear medicine / Clin Nucl Med. 2017 May;42(5):391-393. doi: 10.1097/RLU.0000000000001554.
2017
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Airoldi M; Manfredi M; Tucci M; Buttigliero C; Parente A; Angusti T;

Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer. in Cancer treatment reviews / Cancer Treat Rev. 2017 Mar;54:1-9. doi: 10.1016/j.ctrv.2017.01.002. Epub 2017 Jan 11.
2017
AOU San Luigi di Orbassano

Buttigliero C; Tucci M; Vignani F; Scagliotti GV; Di Maio M;

An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer. in Minerva urologica e nefrologica = The Italian journal of urology and nephrology / Minerva Urol Nefrol. 2017 Aug;69(4):349-358. doi: 10.23736/S0393-2249.16.02746-6. Epub 2016 Dec 22.
2017
AO Ordine Mauriziano
AOU San Luigi di Orbassano

DI Maio M; Scagliotti GV; Aroasio E; Buttigliero C; Berruti A; Bertaglia V; Tucci M; Vignani F;

Zoledronic Acid Dosing Interval for Metastatic Cancer. in JAMA / JAMA. 2017 Apr 11;317(14):1477-1478. doi: 10.1001/jama.2017.2562.
2017
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Di Maio M; Buttigliero C; Tucci M;

Immediate or Delayed Nephrectomy in Patients With Metastatic Renal Cancer Who Are Receiving Targeted Agents: Is the Analysis at Risk for Guarantee-Time Bias? in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2017 Apr 10;35(11):1264. doi: 10.1200/JCO.2016.69.3580. Epub 2017 Feb 6.
2017
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Di Maio M; Vignani F; Tucci M; Buttigliero C;

Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. in BioMed research international / Biomed Res Int. 2017;2017:5618174. doi: 10.1155/2017/5618174. Epub 2017 Jun 7.
2017
AO Ordine Mauriziano
AOU San Luigi di Orbassano

Scagliotti GV; Pignataro D; Vignani F; Buttigliero C; Leone G; Tucci M; Zichi C; Di Maio M;

Cost of illness of urothelial bladder cancer in Italy. in ClinicoEconomics and outcomes research : CEOR / Clinicoecon Outcomes Res. 2017 Jul 24;9:433-442. doi: 10.2147/CEOR.S135065. eCollection 2017.
2017
AOU San Luigi di Orbassano

Gerace C; Montorsi F; Tambaro R; Cartenì G; De Luca S; Tucci M; Martorana G; Basso U; Cardosi L; Teruzzi C;

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. in The Lancet. Oncology / Lancet Oncol. 2016 Sep;17(9):1306-16. doi: 10.1016/S1470-2045(16)30173-5. Epub 2016 Jul 26.
2016
AOU San Luigi di Orbassano

Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;

Androgen deprivation modulates gene expression profile along prostate cancer progression. in Human pathology / Hum Pathol. 2016 Oct;56:81-8. doi: 10.1016/j.humpath.2016.06.004. Epub 2016 Jun 21.
2016
AOU San Luigi di Orbassano

Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I;

Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. in Cancer treatment reviews / Cancer Treat Rev. 2016 Mar;44:61-73. doi: 10.1016/j.ctrv.2016.02.002. Epub 2016 Feb 12.
2016
AOU San Luigi di Orbassano

Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M;

Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. in Future oncology (London, England) / Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18.
2016
AOU San Luigi di Orbassano

Veccia A; Caffo O; De Giorgi U; Di Lorenzo G; Ortega C; Scognamiglio F; Aieta M; Facchini G; Mansueto G; Mattioli R; Procopio G; Zagonel V; D'Angelo A; Spizzo G; Bortolus R; Donini M; Lo Re G; Massari F; Vicario G; Zucali PA; Alesini D; Bonetti A; Mucciarini C; Nicodemo M; Berruti A; Fratino L; Lodde M; Messina C; Perin A; et alii...

Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. in European urology / Eur Urol. 2016 Apr;69(4):563-573. doi: 10.1016/j.eururo.2015.09.013. Epub 2015 Sep 28.
2016
AOU San Luigi di Orbassano

Scagliotti GV; Porpiglia F; Fiori C; Buttigliero C; Vignani F; Tucci M; Bertaglia V; Di Maio M;

The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome. in Endocrine / Endocrine. 2015 Sep;50(1):223-30. doi: 10.1007/s12020-015-0525-x. Epub 2015 Jan 15.
2015
AOU San Luigi di Orbassano

Buttigliero C; Vana F; Bertaglia V; Vignani F; Fiori C; Osella G; Porpiglia F; Tucci M; Scagliotti GV; Berruti A;

Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment. in Oncotarget / Oncotarget. 2015 May 20;6(14):12520-8. doi: 10.18632/oncotarget.3724.
2015
AOU San Luigi di Orbassano

Iuliani M; Pantano F; Buttigliero C; Fioramonti M; Bertaglia V; Vincenzi B; Zoccoli A; Ribelli G; Tucci M; Vignani F; Berruti A; Scagliotti GV; Tonini G; Santini D;

Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. in Urologic oncology / Urol Oncol. 2015 Jun;33(6):265.e15-21. doi: 10.1016/j.urolonc.2015.02.016. Epub 2015 Apr 20.
2015
AOU San Luigi di Orbassano

Caffo O; Ortega C; Di Lorenzo G; Sava T; De Giorgi U; Cavaliere C; Macrini S; Spizzo G; Aieta M; Messina C; Tucci M; Lodde M; Mansueto G; Zucali PA; Alesini D; D'Angelo A; Massari F; Morelli F; Procopio G; Ratta R; Fratino L; Lo Re G; Pegoraro MC; Zustovich F; Vicario G; Ruatta F; Federico P; La Russa F; Burgio SL; et alii...

2015
AOU San Luigi di Orbassano

Caffo O; De Giorgi U; Fratino L; Alesini D; Zagonel V; Facchini G; Gasparro D; Ortega C; Tucci M; Verderame F; Campadelli E; Lo Re G; Procopio G; Sabbatini R; Donini M; Morelli F; Sartori D; Zucali P; Carrozza F; D'Angelo A; Vicario G; Massari F; Santini D; Sava T; Messina C; Fornarini G; La Torre L; Ricotta R; Aieta M; et alii...

Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. in Cancer treatment reviews / Cancer Treat Rev. 2015 Dec;41(10):884-92. doi: 10.1016/j.ctrv.2015.08.002. Epub 2015 Aug 31.
2015
AOU San Luigi di Orbassano

Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV;

Alberta Breakthrough Pain Assessment Tool: A validation multicentre study in cancer patients with breakthrough pain. in European journal of pain (London, England) / Eur J Pain. 2015 Aug;19(7):881-8. doi: 10.1002/ejp.612. Epub 2014 Nov 5.
2015
AOU San Luigi di Orbassano
AOU Città della Salute di Torino

Scagliotti GV; Saini A; Tucci M; Rosato R; Giuliano PL; Ginosa I; Paoletti S; Laciura P; Berruti A; Campagna S; Sperlinga R;

Metastatic castration-resistant prostate cancer: time for innovation. in Future oncology (London, England) / Future Oncol. 2015;11(1):91-106. doi: 10.2217/fon.14.145.
2015
AOU San Luigi di Orbassano

Tucci M; Scagliotti GV; Vignani F;

Circadian variation of breakthrough pain in cancer patients. in European journal of pain (London, England) / Eur J Pain. 2013 Feb;17(2):264-70. doi: 10.1002/j.1532-2149.2012.00184.x. Epub 2012 Jun 19.
2013
AOU San Luigi di Orbassano

Saini A; Tucci M; Tampellini M; Maina D; Bouraouia K; Giuliano PL; Termine A; Castellano M; Campagna S; Laciura P; Berruti A;

Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. in Cancer treatment reviews / Cancer Treat Rev. 2013 Dec;39(8):966-73. doi: 10.1016/j.ctrv.2013.03.003. Epub 2013 Apr 10.
2013
AOU San Luigi di Orbassano

Pia A; Vignani F; Attard G; Tucci M; Bironzo P; Scagliotti G; Arlt W; Terzolo M; Berruti A;

Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle. in Open access journal of urology / Open Access J Urol. 2010 Jul 23;2:109-24. doi: 10.2147/rru.s6573.
2010
AOU San Luigi di Orbassano

Berruti A; Vignani F; Russo L; Bertaglia V; Tullio M; Tucci M; Poggio M; Dogliotti L;

Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease. in Prostate cancer and prostatic diseases / Prostate Cancer Prostatic Dis. 2009;12(1):94-9. doi: 10.1038/pcan.2008.10. Epub 2008 Mar 11.
2009
AOU San Luigi di Orbassano

Tucci M; Mosca A; Lamanna G; Porpiglia F; Terzolo M; Vana F; Cracco C; Russo L; Gorzegno G; Tampellini M; Torta M; Reimondo G; Poggio M; Scarpa RM; Angeli A; Dogliotti L; Berruti A;

Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. in The Journal of urology / J Urol. 2007 Sep;178(3 Pt 1):838-43; quiz 1129. doi: 10.1016/j.juro.2007.05.018. Epub 2007 Jul 16.
2007
AOU San Luigi di Orbassano

Berruti A; Mosca A; Porpiglia F; Bollito E; Tucci M; Vana F; Cracco C; Torta M; Russo L; Cappia S; Saini A; Angeli A; Papotti M; Scarpa RM; Dogliotti L;

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. in British journal of cancer / Br J Cancer. 2005 Sep 19;93(6):633-8. doi: 10.1038/sj.bjc.6602767.
2005
AOU San Luigi di Orbassano

Berruti A; Tucci M; Mosca A; Tarabuzzi R; Gorzegno G; Terrone C; Vana F; Lamanna G; Tampellini M; Porpiglia F; Angeli A; Scarpa RM; Dogliotti L;

2005
AOU San Luigi di Orbassano

Berruti A; Fara E; Tucci M; Tarabuzzi R; Mosca A; Terrone C; Gorzegno G; Fasolis G; Tampellini M; Porpiglia F; De Stefanis M; Fontana D; Bertetto O; Dogliotti L;

2004
AOU San Luigi di Orbassano

Tampellini M; Bitossi R; Brizzi MP; Saini A; Tucci M; Alabiso I; Dogliotti L;

Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases. in The International journal of biological markers / Int J Biol Markers. 2002 Oct-Dec;17(4):244-52. doi: 10.5301/jbm.2008.2194.
2002
AOU San Luigi di Orbassano

Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A;

Background to and management of treatment-related bone loss in prostate cancer. in Drugs & aging / Drugs Aging. 2002;19(12):899-910. doi: 10.2165/00002512-200219120-00002.
2002
AOU San Luigi di Orbassano

Berruti A; Tucci M; Terrone C; Gorzegno G; Scarpa RM; Angeli A; Dogliotti L;

1999
AOU San Luigi di Orbassano

Berruti A; Dogliotti L; Gorzegno G; Torta M; Tampellini M; Tucci M; Cerutti S; Frezet MM; Stivanello M; Sacchetto G; Angeli A;